Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

References

References

• Pham , HT and Soloway , MS . 1997 . High-risk superficial bladder cancer: intravesical therapy for T1, G3 transitional cell carcinoma of the urinary bladder . Semin. Urol. Oncol. , 15 : 147 – 153 .
   Google Scholar
• Jakse G Loidl W Seeber G et al. 1987 Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumour? J. Urol. 137 39 43
   PubMed Web of Science ®Google Scholar
• Parmar , MK , Freedman , LS , Hargreave , TB and Tolley , DA . 1989 . Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) . J. Urol. , 142 ( 2 Pt 1 ) : 284 – 288 .
   Google Scholar
• Pagano , F , Garbeglio , A , Milani , C , Bassi , P and Pegoraro , V . 1987 . Prognosis of bladder cancer. 1. Risk factors in superficial transitional cell carcinoma . Eur. Urol. , 13 ( 3 ) : 145 – 149 .
   Google Scholar
• Soloway , M . 1980 . The management of superficial bladder cancer . Cancer , 45 : 1856 – 1865 .
   PubMed Web of Science ®Google Scholar
• Sarosdy , MF and Lamm , DL . 1989 . Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer . J. Urol. , 142 : 719 – 722 .
   PubMed Web of Science ®Google Scholar
• Lamm DL Blumenstein BA Crawford ED et al. 1991 A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder N. Engl. J. Med. 325 1205 1209
   PubMed Web of Science ®Google Scholar
• Morales , A , Eidinger , D and Bruce , AW . 1976 . Intracavity BCG in the treatment of superficial bladder tumors . J. Urol. , 116 : 180 – 183 .
   PubMed Web of Science ®Google Scholar
• Lamm , DL . 1992 . Carcinoma in situ . Urol. Clin. North Am. , 19 : 499 – 508 .
   PubMed Web of Science ®Google Scholar
• Lamm , DL . 1992 . Long-term results of intravesical therapy for superficial bladder cancer . Urol. Clin. N. Am. , 19 ( 3 ) : 573 – 580 .
   PubMed Web of Science ®Google Scholar
• Gohji K Nomi M Okamoto M et al. 1999 Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder Urology 53 308 313
   PubMed Web of Science ®Google Scholar
• Hurle R Losa A Manzetti A et al. 1999 Intravesical bacillus Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up Urology 54 258 263
   PubMed Web of Science ®Google Scholar
• Baniel J Grauss D Engelstein D et al. 1998 Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder Urology 52 785 789
   Google Scholar
• Hurle R Losa A Ranieri A et al. 1996 Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy J. Urol. 156 1602 1605
   Web of Science ®Google Scholar
• Lamm , DL , Stogdill , VD , Stogdill , BJ and Crispen , RG . 1986 . Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer . J. Urol. , 135 ( 2 ) : 272 – 274 .
   PubMed Web of Science ®Google Scholar
• Fleming D Cooper JS Henson DE et al. 1997 ASCC Cancer Staging Manual 5th Ed. Lippincott-Raven Philadelphia
   Google Scholar
• Dalbagni , G , Rechtschaffen , T and Herr , HW . 1999 . Transurethral biopsy of the bladder necessary after three months to evaluate response to bacillus Calmette-Guerin therapy? . J. Urol. , 162 : 708 – 709 .
   PubMedGoogle Scholar
• Vicente J Laguna MP Duarte D et al. 1991 Carcinoma in situ as a prognostic factor for G3, PT1 bladder tumors Br. J. Urol. 68 380 382
   Google Scholar
• Anderson , G , Johansson , S and Nilsson , S . 1980 . The significance of lamina propria invasion on the prognosis of patients with bladder turnors . J. Urol. , 124 : 23 – 26 .
   Google Scholar
• England , HR , Paris , AM and Blandy , JP . 1981 . The correlation of T1 bladder tumour history with prognosis and follow-up requirements . Br. J. Urol. , 53 : 593 – 597 .
   PubMedGoogle Scholar
• Herr , HW . 1997 . Tumor progression and survival in patients with T1G3 bladder tumours: 15-year outcome . Br. J. Urol. , 80 : 762 – 765 .
   PubMedGoogle Scholar
• Schmitz-Drager , BJ and Muller , M . 1998 . Intravesical treatment of bladder cancer: current problems and needs . Urol. Int. , 61 : 199 – 205 .
   Google Scholar
• Naito S Kotoh S Omoto T et al. 1998 Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapermil versus doxorubicin alone Cancer Chemother. Pharmacol. 42 367 372
   PubMed Web of Science ®Google Scholar
• Morgia , G , Mauceri , G , Mazzone , G and Motta , M . 1992 . Retrospective analysis on drug tolerance in the prophylaxis of superficial urothelioma neoplastic recurrence . Arch. Ital. Urol. , 64 : 313 – 317 .
   Google Scholar
• Pagano F Bassi P Milani C et al. 1991 A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 146 32 35
   PubMed Web of Science ®Google Scholar
• Herr HW Wartinger DD Fair WR et al. 1992 BCG therapy for superficial bladder cancer: a 10-year follow-up J. Urol. 147 1020 1023
   PubMed Web of Science ®Google Scholar